Showing 1 - 7 results of 7 for search 'Suthinee Ithimakin', query time: 0.04s
Refine Results
-
1
Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis by Nuttapong Ngamphaiboon, Suthinee Ithimakin, Teerada Siripoon, Nattaya Sintawichai, Virote Sriuranpong
Published 2021-11-01
Article -
2
Pathological and Oncologic Outcomes of Consolidation Chemotherapy in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiation by Thikhamporn Tawantanakorn, Thawatchai Akaraviputh, Vitoon Chinswangwatanakul, Suthinee Ithimakin, Janjira Petsuksiri, Atthaphorn Trakarnsanga
Published 2023-04-01
Article -
3
Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome by Concord Wongkraisri, Kriengkrai Chusuwanrak, Apirom Laocharoenkeat, Leena Chularojanamontri, Akarin Nimmannit, Suthinee Ithimakin
Published 2025-02-01
Article -
4
Outcomes of Patients With Breast Cancer Treated With or Without Internal Mammary Irradiation: A Single-Center, Retrospective Propensity Score–Matched Study by Tanun Jitwatcharakomol, MD, Jiraporn Setakoranukul, MD, Suthinee Ithimakin, MD, Rungroj Krittayaphong, MD, Kullathorn Thephamongkhol, MD
Published 2023-01-01
Article -
5
Efficacy and Safety of Short Intravenous Hydration for Preventing Nephrotoxicity From High-Dose Cisplatin: A Randomized, Open-Label, Phase II Trial by Apichart Jantarat, Lucksamon Thamlikitkul, Kullathorn Thephamongkhol, Jiraporn Setakornnukul, Pochamana Phisalprapa, Chayanis Kositamongkol, Thatsaphan Srithongkul, Suthinee Ithimakin
Published 2025-01-01
Article -
6
Does Extending the Waiting Time of Low-Rectal Cancer Surgery after Neoadjuvant Chemoradiation Increase the Perioperative Complications? by Kittinut Timudom, Natthawut Phothong, Thawatchai Akaraviputh, Vitoon Chinswangwatanakul, Ananya Pongpaibul, Janjira Petsuksiri, Suthinee Ithimakin, Atthaphorn Trakarnsanga
Published 2016-01-01
Article -
7
Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-w... by Thanate Dajsakdipon, Thiti Susiriwatananont, Concord Wongkraisri, Suthinee Ithimakin, Napa Parinyanitikul, Archara Supavavej, Arunee Dechaphunkul, Patrapim Sunpaweravong, Sunee Neesanun, Charuwan Akewanlop, Thitiya Dejthevaporn, TSCO Breast Oncology Group
Published 2024-08-01
Article